Pancreatic cancer vaccine shows promise

Experimental vaccine for common cancer shows potential in clinical trial
A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study co-author Dr. Vinod Balachandran talks about the impact on future cancer care.
mRNA vaccines show promise against pancreatic cancer in early trial
Personalized mRNA vaccines show promise as a pancreatic cancer treatment, according to a small, early stage trial published Wednesday.
Vaccine shows promise for treating pancreatic cancer, study shows
A personalized mRNA vaccine appeared to reduce the chances of pancreatic cancer returning after surgery, according to a study published in the journal Nature.
Vaccine targeting pancreatic cancer shows promise in new study of clinical trial
A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage pancreatic cancer patients.
Can mRNA vaccines help in the fight against pancreatic cancer?
There is new hope in the fight against pancreatic cancer after early trials showed that personalized mRNA vaccines can target and reduce malignant tumors. NBC News medical contributor Dr. Kavita Patel reports on the vaccine’s success against pancreatic cancer,
A Vaccine For Pancreatic Cancer Continues To Show Promise
In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three years later.
Trial shows promise of mRNA vaccines in treating pancreatic cancer
The phase 1 trial results, published Feb. 19 in Nature, evaluated the personalized mRNA neoantigen vaccine autogene cevumeran in combination with surgery, immunotherapy drug atezolizumab and chemotherapy in patients with pancreatic ductal adenocarcinoma.
The Daily Pennsylvanian3d
Here’s how Penn researchers are using mRNA technology to treat cancer, celiac disease
Penn researchers are developing new treatments using mRNA technology to combat a range of diseases, namely celiac disease ...
Analyst Confident In Moderna's Cancer Vaccine But Highlights Other Challenges
EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...
Medpage Today on MSN1d
Researchers Describe Rare Syndrome After COVID Vaccine
Immune cell populations of people with post-vaccination syndrome had lower levels of effector CD4 T cells and higher levels ...
Moderna, Inc.: Working Hard But Competition Is Working Harder
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Cancer vaccine for women to be available in six months; check details
The vaccine will be administered to girls between the ages of nine and 16 as part of the government’s initiative to address the rising number of cancer cases in the country.